Oncologists Embrace BRAF Testing, Coast Through Managed Care With New Melanoma Drugs

Six-figure pricing in oncology is becoming increasingly common and has raised eyebrows, but a new survey of new melanoma drugs Yervoy and Zelboraf suggests that so far high price is not an obstacle to adoption. So soon after launch, it’s still unclear if one treatment will emerge dominant in first-line treatment.